戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1     All patients recovered after intravenous immunoglobulin therapy.
2 eresis (PPH) in conjunction with intravenous immunoglobulin therapy.
3 uble-blind, placebo-controlled trials of RSV immunoglobulin therapy.
4 e illness may be ameliorated by passive oral immunoglobulin therapy.
5 the anti-inflammatory activity of human i.v. immunoglobulin therapy.
6 taminated, open wounds with immunization and immunoglobulin therapy.
7 f response to corticosteroid and intravenous immunoglobulin therapy, a 3-day course of plasmapheresis
8 Group 1 and 2 patients received no hepatitis immunoglobulin therapy after transplantation and receive
9                 He also received intravenous immunoglobulin therapy and his vision has stabilized.
10 d on novel therapeutic interventions such as immunoglobulin therapy and immunosuppressive therapy in
11 analysis of anti-Hbs elimination can improve immunoglobulin therapy and prevent recurrence of clinica
12 f juvenile rheumatoid arthritis, intravenous immunoglobulin therapy appeared ineffective in the disea
13 imen using plasmapheresis and/or intravenous immunoglobulin therapy, but underlying mechanisms that c
14  must be in some doubt, although intravenous immunoglobulin therapy has been shown to be beneficial i
15           The anemia promptly remitted after immunoglobulin therapy in 3 of 4 treated patients.
16  November 2002 to November 2004, intravenous immunoglobulin therapy (IVIG) was administered to patien
17 an update of the evidence-based guideline on immunoglobulin therapy, last published in 2006.
18 gy in 80 patients established (>6 months) on immunoglobulin therapy; prospective analysis of HBV sero
19 atory properties associated with intravenous immunoglobulin therapy require the sialic acid modificat
20          With increasing patient survival on immunoglobulin therapy, there is an increasing focus on
21   In response to the 2014 outbreak, an ovine immunoglobulin therapy was developed, termed EBOTAb.
22 roid pulse therapy and high-dose intravenous immunoglobulin therapy was successful in complete re-epi
23 anaged effectively with monthly prophylactic immunoglobulin therapy whereas SSCLS frequently does not
24 nd controversial indications for intravenous immunoglobulin therapy, with special emphasis on its mec